Problem

Nabla addresses the administrative and cognitive load of clinical documentation: clinicians must listen, synthesize, format notes, and complete coding while maintaining a patient relationship. The pain is also economic: screen-based documentation competes with attention during the encounter and consumes scarce clinician time and capacity. The killer use case is an ambient assistant that captures the patient-clinician conversation and turns it into a structured note, reducing the need to type throughout the visit. Because documentation also feeds coding and final code submission, improving this workflow can support greater efficiency, although the available research does not quantify the savings.

Product / Service

Nabla provides a clinical-intelligence layer embedded in existing EHR workflows. Its ambient documentation product captures the clinical conversation and automatically generates structured notes, while its dictation capability provides clinical-grade speech recognition inside Epic and other major EHRs. The platform is designed to support care before, during, and after the visit rather than functioning only as a note-taking tool.

The offering has expanded into coding suggestions grounded in clinical documentation and AMA guidelines, broader clinical workflow tools, and agentic AI for multi-step clinical and administrative tasks. Nabla positions the product as enterprise-grade infrastructure for secure deployment across health systems, with clinicians retaining control over final coding decisions. The benefit is a faster, more flexible documentation process that lets clinicians focus more on patients while reducing manual work.

Market

Nabla competes in the ambient clinical intelligence and AI medical-scribe market, with a broader position in clinical workflow automation. The most prominent direct competitors identified in the research are Abridge, Ambience Healthcare, and Suki; Microsoft-owned Nuance is a major adjacent incumbent in the same category. The market is crowded and expected to consolidate as health systems choose among ambient documentation and broader clinical AI platforms.

Nabla is commercial and not pre-revenue. The latest disclosed operating figures in the research, from June 2025, report fivefold revenue growth over the preceding six months, more than 85,000 clinicians supported, 20 million annual encounters, and adoption across more than 130 healthcare organizations. Those figures indicate substantial enterprise traction, although the available evidence does not provide audited revenue, profitability, or a newer 2026 operating update.